For a change, let’s hear some good news from the United Kingdom after a month that saw two terrorist attacks and now a tragic apartment fire in London where casualties are mounting as we speak.
The good news is that cannabinoid biotechnology company MediPen Ltd. is launching its own dedicated marijuana research facility this summer, and it will provide a platform for anyone looking to utilize its 1,800 square-foot facilities for the purposes of innovation in the area of medicinal cannabis.
As the first biotechnology company to develop a vapor product, MediPen Ltd. has already enjoyed success selling their non-psychoactive CBD vaporizers, which are currently in the process of securing a license from the British Home Office.
Their goal is to import and work with controlled compounds, including THC, for further research.
MediPen intends to further study vaporizers to treat cancer patients with the aim of minimizing the negative impact of chemotherapy-based treatments, such as nausea and vomiting, as well as attempting to suppress metastasis through inhibiting the proliferation of cancer cells.
Among the most respected legal cannabinoid providers in the UK, last summer MediPen entered into a contract with the country’s National Health Service (NHS) to improve the quality and safety of cannabinoid goods all around.
Their devices were tested by an NHS unit, an unprecedented and important step that helped focus and increase attention on the medical benefits of cannabis.
“As it stands, there is a significant amount of scientific data available detailing the powerful effects of cannabinoids within cell culture systems and in vivo,” a MediPen representative told the Independent. “However, we plan to be amongst the first in the world to begin clinical trials on humans.”
While GW Pharmaceuticals is also developing CBD-based medicine from its own facility, MediPen’s will be a little different in terms of its public availability.
MediPen intends to allow the use of its facilities to founders of other cannabis-based innovations, who will also be encouraged to take advantage of their established R&D network, state of the art, in-house testing, as well as on-board business and legal advice.
